KR20220141302A - 코로나 바이러스 백신 제제 - Google Patents

코로나 바이러스 백신 제제 Download PDF

Info

Publication number
KR20220141302A
KR20220141302A KR1020227029337A KR20227029337A KR20220141302A KR 20220141302 A KR20220141302 A KR 20220141302A KR 1020227029337 A KR1020227029337 A KR 1020227029337A KR 20227029337 A KR20227029337 A KR 20227029337A KR 20220141302 A KR20220141302 A KR 20220141302A
Authority
KR
South Korea
Prior art keywords
cov
amino acids
fraction
seq
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227029337A
Other languages
English (en)
Korean (ko)
Inventor
게일 스미스
마이클 제이 마서리
징-후이 티엔
Original Assignee
노바백스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/997,001 external-priority patent/US10953089B1/en
Application filed by 노바백스, 인코포레이티드 filed Critical 노바백스, 인코포레이티드
Publication of KR20220141302A publication Critical patent/KR20220141302A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020227029337A 2020-01-27 2021-01-27 코로나 바이러스 백신 제제 Pending KR20220141302A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202062966271P 2020-01-27 2020-01-27
US62/966,271 2020-01-27
US202062976858P 2020-02-14 2020-02-14
US62/976,858 2020-02-14
US202062983180P 2020-02-28 2020-02-28
US62/983,180 2020-02-28
US202063048945P 2020-07-07 2020-07-07
US63/048,945 2020-07-07
US202063051706P 2020-07-14 2020-07-14
US63/051,706 2020-07-14
US202063054182P 2020-07-20 2020-07-20
US63/054,182 2020-07-20
US16/997,001 2020-08-19
US16/997,001 US10953089B1 (en) 2020-01-27 2020-08-19 Coronavirus vaccine formulations
US202063129392P 2020-12-22 2020-12-22
US63/129,392 2020-12-22
PCT/US2021/015220 WO2021154812A1 (en) 2020-01-27 2021-01-27 Coronavirus vaccine formulations

Publications (1)

Publication Number Publication Date
KR20220141302A true KR20220141302A (ko) 2022-10-19

Family

ID=77079351

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227029337A Pending KR20220141302A (ko) 2020-01-27 2021-01-27 코로나 바이러스 백신 제제

Country Status (14)

Country Link
US (1) US20230070886A1 (https=)
EP (1) EP4097123A4 (https=)
JP (2) JP7792339B2 (https=)
KR (1) KR20220141302A (https=)
CN (1) CN115720581A (https=)
AU (1) AU2021214064A1 (https=)
BR (1) BR112022014830A2 (https=)
CA (1) CA3165371A1 (https=)
GB (1) GB2610070A (https=)
IL (1) IL295142A (https=)
MX (1) MX2022009167A (https=)
TW (1) TW202142555A (https=)
WO (1) WO2021154812A1 (https=)
ZA (1) ZA202401922B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
WO2022235663A1 (en) * 2021-05-05 2022-11-10 Novavax, Inc. Coronavirus and influenza compositions and methods for using them
CN113773372B (zh) * 2021-08-15 2024-08-02 北京科兴中维生物技术有限公司 重组蛋白及其制备方法和应用
CN116041448B (zh) * 2021-08-26 2025-05-13 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
EP4436984A1 (en) * 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Coronavirus immunogen compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20240125935A (ko) * 2021-11-30 2024-08-20 노바백스, 인코포레이티드 코로나바이러스 백신 제형물
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
EP4709741A1 (en) * 2023-05-12 2026-03-18 Icosavax, Inc. Coronavirus spike glycoprotein receptor binding domains and uses thereof
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1508615A1 (en) * 2003-08-18 2005-02-23 Amsterdam Institute of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
US20070124833A1 (en) * 2005-05-10 2007-05-31 Abad Mark S Genes and uses for plant improvement
JP5813513B2 (ja) * 2008-12-09 2015-11-17 ノババックス，インコーポレイテッド 修飾ｒｓｖｆタンパク質及びその使用方法
US20130122032A1 (en) * 2011-09-30 2013-05-16 Gale Smith Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
KR102399854B1 (ko) * 2013-09-19 2022-05-19 노바백스, 인코포레이티드 면역원성 중동호흡기증후군 코로나바이러스 (ΜＥＲＳ-ＣｏＶ) 조성물 및 방법
EP4494650A3 (en) * 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US20170354729A1 (en) * 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
EP4599847A3 (en) * 2016-10-25 2025-11-12 Trustees of Dartmouth College Prefusion coronavirus spike proteins and their use
MA47790A (fr) * 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
CN111499692B (zh) * 2020-06-16 2020-12-04 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用

Also Published As

Publication number Publication date
CN115720581A (zh) 2023-02-28
BR112022014830A2 (pt) 2022-09-27
EP4097123A1 (en) 2022-12-07
IL295142A (en) 2022-09-01
TW202142555A (zh) 2021-11-16
JP2026026092A (ja) 2026-02-16
GB202212336D0 (en) 2022-10-12
ZA202401922B (en) 2025-04-30
GB2610070A (en) 2023-02-22
MX2022009167A (es) 2022-08-17
JP7792339B2 (ja) 2025-12-25
US20230070886A1 (en) 2023-03-09
AU2021214064A1 (en) 2022-08-18
WO2021154812A8 (en) 2022-02-24
EP4097123A4 (en) 2024-02-14
WO2021154812A1 (en) 2021-08-05
JP2023512648A (ja) 2023-03-28
CA3165371A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
US11253586B2 (en) Coronavirus vaccine formulations
JP7792339B2 (ja) コロナウイルスワクチン製剤
US20220332765A1 (en) Coronavirus vaccine formulations
US20250025549A1 (en) Coronavirus vaccine formulations
EP3658118A1 (en) Methods and compositions for treating respiratory disease
RU2845642C1 (ru) Вакцинные составы против коронавируса
WO2020176524A1 (en) Methods for preventing disease or disorder caused by rsv infection
HK40088999A (zh) 冠状病毒疫苗配制品
KR20250175335A (ko) Sars-cov-2 백신 조성물
CN117769433A (zh) 冠状病毒疫苗制剂
CN118613279A (zh) 冠状病毒疫苗制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000